Scully C, Beyli M, Ferreiro M C, Ficarra G, Gill Y, Griffiths M, Holmstrup P, Mutlu S, Porter S, Wray D
Eastman Dental Institute for Oral Health Care Sciences, University of London, United Kingdom.
Crit Rev Oral Biol Med. 1998;9(1):86-122. doi: 10.1177/10454411980090010501.
Lichen planus (LP) is a relatively common disorder of the stratified squamous epithelia, which is, in many ways, an enigma. This paper is the consensus outcome of a workshop held in Switzerland in 1995, involving a selection of clinicians and scientists with an interest in the condition and its management. The oral (OLP) eruptions usually have a distinct clinical morphology and characteristic distribution, but OLP may also present a confusing array of patterns and forms, and other disorders may clinically simulate OLP. Lesions may affect other mucosae and/or skin. Lichen planus is probably of multifactorial origin, sometimes induced by drugs or dental materials, often idiopathic, and with an immunopathogenesis involving T-cells in particular. The etiopathogenesis appears to be complex, with interactions between and among genetic, environmental, and lifestyle factors, but much has now been clarified about the mechanisms involved, and interesting new associations, such as with liver disease, have emerged. The management of lichen planus is still not totally satisfactory, and there is as yet no definitive treatment, but there have been advances in the control of the condition. There is no curative treatment available; immunomodulation, however, can control the condition. Based on the observed increased risk of malignant development, OLP patients should be offered regular follow-up examination from two to four times annually and asked to report any changes in their lesions and/or symptoms. Follow-up may be particularly important in patients with atrophic/ulcerative/erosive affections of the tongue, the gingiva, or the buccal mucosa. Much more research is required into the genetic and environmental aspects of lichen planus, into the premalignant potential, and into the possible associations with chronic liver, and other disorders. More clinical studies are required into the possible efficacy of immunomodulatory drugs such as pentoxifylline and thalidomide.
扁平苔藓(LP)是一种相对常见的复层鳞状上皮疾病,在很多方面都是一个谜。本文是1995年在瑞士举办的一次研讨会的共识成果,参与人员包括对该病及其治疗感兴趣的临床医生和科学家。口腔扁平苔藓(OLP)皮疹通常具有独特的临床形态和特征性分布,但OLP也可能呈现出一系列令人困惑的模式和形式,且其他疾病在临床上可能会模拟OLP。病变可能累及其他黏膜和/或皮肤。扁平苔藓可能是多因素起源,有时由药物或牙科材料诱发,通常为特发性,其免疫发病机制尤其涉及T细胞。病因发病机制似乎很复杂,遗传、环境和生活方式因素之间存在相互作用,但目前已经明确了许多相关机制,并且出现了一些有趣的新关联,如与肝病的关联。扁平苔藓的治疗仍不完全令人满意,目前尚无明确的治疗方法,但在病情控制方面已有进展。没有可用的治愈性治疗方法;然而,免疫调节可以控制病情。基于观察到的恶性发展风险增加,应每年为OLP患者提供2至4次定期随访检查,并要求他们报告病变和/或症状的任何变化。对于舌、牙龈或颊黏膜有萎缩性/溃疡性/糜烂性病变的患者,随访可能尤为重要。需要对扁平苔藓的遗传和环境方面、癌前潜能以及与慢性肝病和其他疾病的可能关联进行更多研究。需要更多关于免疫调节药物如己酮可可碱和沙利度胺可能疗效的临床研究。